시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 바이오베터 시장 보고서(2024년)
Biobetters Global Market Report 2024
상품코드 : 1509591
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 5,000 ￦ 6,926,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 7,500 ￦ 10,389,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 10,000 ￦ 13,853,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

바이오베터 시장 규모는 향후 몇 년 동안 급성장할 것으로 예상되며, 2028년까지 연평균 성장률(CAGR) 11.8%로 1,059억 4,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 바이오테크놀러지의 발전, 개인 맞춤형 의료에 대한 관심 증가, 바이오제약 기업의 파이프라인 확장, 만성질환 유병률 증가, 유리한 규제 환경, R&D 투자 증가, 첨단 의료 인프라에 기인합니다. 예측 기간 동안 주요 동향으로는 신규 바이오베터 개발, 단백질 공학 및 합리적 설계의 발전, 특정 치료 분야에 대한 집중, 차세대 시퀀싱(NGS) 기술 개발, 고성능 스크리닝(HTS) 기술 발전 등이 있습니다.

만성 신장 질환의 유병률 증가는 향후 바이오베터 시장의 성장을 촉진할 것으로 예상됩니다. 만성콩팥병(CKD)은 신장 기능을 손상시켜 결국 신부전으로 이어지는 장기적인 질병으로, 인구 고령화, 당뇨병 및 고혈압 유병률 증가, 식습관 장애, 좌식 생활습관, 환경오염, 진단 능력 향상 등으로 인해 CKD 유병률이 증가하고 있습니다. 바이오베터는 기존 생물학적 제제 치료와 비교해 유효성 향상, 부작용 감소, 투여 요법 개선, 안정성 향상 등을 통해 CKD 관리에 도움을 주고 환자의 예후를 개선할 수 있습니다. 예를 들어, 호주에 본사를 둔 공중보건 정부 기관인 호주보건복지연구소(AIHW)에 따르면, 2021년 호주에서 CKD로 인한 사망자 수는 약 2만 명에 달했으며, 이는 그 해 전체 사망률의 12%를 차지합니다. 따라서 만성 신장 질환의 유병률 증가는 바이오베터 시장의 성장을 주도하고 있습니다.

자가면역질환의 유병률 증가는 향후 바이오베터 시장의 성장을 촉진할 것으로 예상됩니다. 자가면역질환은 면역체계가 건강한 세포를 잘못 공격하는 질환입니다. 자가면역질환의 유병률은 유전적 소인, 환경적 영향, 생활습관 변화 등의 요인으로 인해 증가하고 있습니다. 바이오베터는 기존 생물학적 제제 치료와 비교했을 때 효능을 개선하고 부작용을 줄이며, 투여 요법을 개선하고 안정성을 향상시켜 자가면역질환을 보다 효과적이고 내약성 있게 관리할 수 있도록 돕고 있습니다. 예를 들어, 호주 보건 복지 연구소(AIHW)에 따르면 2023년 12월 류마티스 관절염은 전체 질병 부담의 2.0%를 차지했으며 2021년에는 1,145 명이 사망하여 인구 10만 명당 3.2 명이 사망하여 전체 사망자의 0.7%를 차지했습니다. 따라서 자가면역질환의 유병률 증가가 바이오베터 시장의 성장을 주도하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 거시경제 시나리오

제5장 세계의 시장 규모와 성장

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 상황과 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 경쟁 벤치마킹

제33장 경쟁 대시보드

제34장 주요 인수합병

제35장 향후 전망과 잠재적 분석

제36장 부록

ksm
영문 목차

영문목차

Biobetters are biologic drugs that are similar to existing biologics but have been enhanced to offer improved efficacy, safety, or other clinical benefits. These enhancements may include better dosing regimens, reduced side effects, increased stability, or more convenient administration methods, providing a competitive edge over the original biologics.

The main drug classes of biobetters include erythropoietin biobetters, granulocyte-colony stimulating factor (G-CSF) biobetters, interferon biobetters, insulin biobetters, monoclonal antibody biobetters, antihemophilic factors, and others. Erythropoietin biobetters are enhanced versions of erythropoietin, a hormone that increases red blood cell production. Various routes of administration for biobetters include oral, subcutaneous, inhaled, and intravenous. These drugs address a range of disease indications such as diabetes, cancer, renal disease, neurodegenerative diseases, genetic disorders, and hemophilia. They are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The biobetters market research report is one of a series of new reports from The Business Research Company that provides biobetters market statistics, including biobetters industry global market size, regional shares, competitors with a biobetters market share, detailed biobetters market segments, market trends and opportunities, and any further data you may need to thrive in the biobetters industry. This biobetters market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The biobetters market size has grown rapidly in recent years. It will grow from $60.73 billion in 2023 to $67.81 billion in 2024 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to an increased understanding of disease mechanisms, growing healthcare expenditure, enhanced manufacturing technologies, technological innovations in drug delivery, advancements in protein engineering, and increased demand for improved therapeutic efficacy.

The biobetters market size is expected to see rapid growth in the next few years. It will grow to $105.94 billion in 2028 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to advancements in biotechnology, a growing emphasis on personalized medicine, expanding pipelines of biopharmaceutical companies, the rising prevalence of chronic diseases, favorable regulatory landscapes, heightened investments in research and development, and advanced healthcare infrastructure. Major trends in the forecast period include the development of novel biobetters, progress in protein engineering and rational design, a focus on specific therapeutic areas, the development of next-generation sequencing (NGS) technologies, and advances in high-throughput screening (HTS) technologies.

The rising incidence of chronic kidney diseases is expected to propel the growth of the biobetters market going forward. Chronic kidney disease (CKD) is a long-term illness that impairs kidney function and eventually leads to kidney failure. The prevalence of CKD is increasing due to aging demographics, higher incidences of diabetes and hypertension, poor dietary habits, sedentary lifestyles, environmental pollution, and improved diagnostic capabilities. Biobetters aid in managing CKD by offering enhanced efficacy, reduced side effects, better dosing regimens, and improved stability compared to original biologic treatments, leading to better patient outcomes. For example, according to the Australian Institute of Health and Welfare (AIHW), an Australia-based government agency for public health, approximately 20,000 deaths in Australia in 2021 were linked to CKD, accounting for 12% of the total mortality rate that year. Therefore, the rising incidence of chronic kidney diseases is driving the growth of the biobetters market.

The increasing prevalence of autoimmune diseases is expected to propel the growth of the biobetters market going forward. Autoimmune diseases are disorders where the immune system mistakenly attacks healthy cells. The prevalence of autoimmune diseases is rising due to factors such as genetic predisposition, environmental influences, and lifestyle changes. Biobetters help manage autoimmune disorders by providing enhanced efficacy, reduced side effects, improved dosing regimens, and increased stability compared to original biologic treatments, leading to more effective and tolerable management of these conditions. For instance, in December 2023, according to the Australian Institute of Health and Welfare (AIHW), rheumatoid arthritis accounted for 2.0% of the total disease burden in 2023. In 2021, it caused 1,145 deaths, equivalent to 3.2 deaths per 100,000 people, representing 0.7% of all fatalities. Therefore, the increasing prevalence of autoimmune diseases is driving the growth of the biobetters market.

Major companies in the biobetters market are developing biobetters for subcutaneous administration to improve patient convenience, enhance therapeutic outcomes, and reduce healthcare costs. Subcutaneous administration of biobetters offers a more convenient alternative to intravenous infusion, potentially improving patient compliance and healthcare delivery efficiency. For instance, in May 2023, Celltrion, a South Korean-based biopharmaceutical company, obtained approval from the Brazilian Health Regulatory Agency for their Remsima SC biobetters. This innovative biobetter version of their infliximab biosimilar, Remsima, is the world's only infliximab offering subcutaneous administration. Remsima SC improves upon a biosimilar by enhancing its accessibility and effectiveness, specifically indicated for inflammatory bowel diseases, including Crohn's disease and ulcerative colitis. Remsima SC offers patients a more convenient and potentially more effective treatment option.

Major companies operating in the biobetters market are Pfizer Inc., Johnson & Johnson, Merck & Co Inc., AbbVie Inc., Bayer AG, Sanofi Aventis LLC, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, F Hoffmann La Roche Ltd., Eli Lilly and Co Ltd., Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc, CSL Behring GmbH, Biogen Inc., GRIFOLS USA LLC, Celltrion Inc., Lonza Group AG, Ionis Pharmaceuticals Inc., Incyte Corporation, Amicus Therapeutics Inc., Genentech Inc., Sun Pharmaceutical Industries

North America was the largest region in the biobetters market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biobetters market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the biobetters market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The biobetters market consists of sales of next-generation biologics, improved formulation products, and biosimilar drugs. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biobetters Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on biobetters market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for biobetters? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biobetters market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

Scope

Table of Contents

1. Executive Summary

2. Biobetters Market Characteristics

3. Biobetters Market Trends And Strategies

4. Biobetters Market - Macro Economic Scenario

5. Global Biobetters Market Size and Growth

6. Biobetters Market Segmentation

7. Biobetters Market Regional And Country Analysis

8. Asia-Pacific Biobetters Market

9. China Biobetters Market

10. India Biobetters Market

11. Japan Biobetters Market

12. Australia Biobetters Market

13. Indonesia Biobetters Market

14. South Korea Biobetters Market

15. Western Europe Biobetters Market

16. UK Biobetters Market

17. Germany Biobetters Market

18. France Biobetters Market

19. Italy Biobetters Market

20. Spain Biobetters Market

21. Eastern Europe Biobetters Market

22. Russia Biobetters Market

23. North America Biobetters Market

24. USA Biobetters Market

25. Canada Biobetters Market

26. South America Biobetters Market

27. Brazil Biobetters Market

28. Middle East Biobetters Market

29. Africa Biobetters Market

30. Biobetters Market Competitive Landscape And Company Profiles

31. Biobetters Market Other Major And Innovative Companies

32. Global Biobetters Market Competitive Benchmarking

33. Global Biobetters Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Biobetters Market

35. Biobetters Market Future Outlook and Potential Analysis

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기